BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 20, 2020
View Archived Issues
Enrollment ongoing in phase I/II study of oral BDTX-189 in advanced solid tumors
Read More
Sanofi initiates phase III study of SAR-408701 in CEACAM5-positive metastatic nonsquamous NSCLC
Read More
Novel muraminomicin derivatives with potent activity in MRSA infection models
Read More
OXi-4503 in combination with ARA-C shows safety and early clinical efficacy in AML
Read More
ASIT Biotech publishes phase III data for gp-ASIT+ grass allergen peptide immunotherapy
Read More
Suzhou Mednes Pharma Tech patents hedgehog signaling inhibitors
Read More
Roche discloses new EGFR mutant inhibitors
Read More
B cells help T cells succeed during checkpoint blockade
Read More
Single transcription factor enables chronic toxoplasma infection
Read More
AlzeCure Pharma presents Trk-A and/or Trk-B and/or Trk-C modulators
Read More
Meiji Seika Pharma describes new PDE4 inhibitors
Read More
New compounds for Huntington's disease presented by PTC Therapeutics
Read More
Pfizer begins phase III study of PF-06801591 in high-risk nonmuscle invasive bladder cancer
Read More
Xalud starts phase II study of XT-150 for pain due to knee osteoarthritis
Read More
SUMOylation inhibition enhances targeting of farnesoid X receptor for liver fibrosis
Read More
Kadmon discloses new SLC2A3 inhibitors
Read More
Oncogene Ras affects memory consolidation
Read More
Phase III study of surufatinib in pancreatic neuroendocrine tumors stopped early for efficacy
Read More